HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV

Science

Volumn 271, Issue 5253, 1996, Pages 1291-1293

  Soto Ramirez, Luis E ^a   Renjifo, Boris ^a   McLane, Mary F ^a   Marlink, Richard ^a   O'Hara, Cari ^b   Sutthent, Ruengpung ^c   Wasi, Chantapong ^c   Vithayasai, Prakong ^d   Vithayasai, Vicharn ^d   Apichartpiyakul, Chatchawann ^d   Auewarakul, Prasert ^a   Peña Cruz, Victor ^a   Chui, Dao Shan ^a   Osathanondh, Rapin ^e   Mayer, Kenneth ^f,g,h   Lee, Tun Hou ^a   Essex, Max ^a  

^a Harvard AIDS Institute   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d CHIANG MAI UNIVERSITY   (Thailand)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f FENWAY INSTITUTE   (United States)

^g MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^h BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; HETEROSEXUALITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LANGERHANS CELL; NONHUMAN; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; VAGINA; VIRUS CELL INTERACTION; VIRUS TRANSMISSION; VIRUS TYPING;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0345717207     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.271.5253.1291     Document Type: Article

References (38)

1. P. Plot and M. Laga, in Textbook of AIDS Medicine, S. Broder, T. C. Mengan Jr., D. Bolognesi, Eds. (Williams and Wilkins, Baltimore, 1994), pp. 109-132.
2. B G. Weniger, Y Takebe, C-Y. Ou, S. Yamazaki, AIDS 8, 13s (1994).
3. S. Y. Chu, R. L Berkelman, J. Curran, in AIDS: Etiology, Diagnosis, Treatment and Prevention, V. T. DeVita Jr. et al., Eds (Lippincott, Philadelphia, 1992), pp. 99-109.
4. J. Louwagie et al , AIDS Res. Hum. Retroviruses 9, 147s (1993); G Myers, ibid., p 697.
5. J. Louwagie et al , AIDS Res. Hum. Retroviruses 9, 147s (1993); G Myers, ibid., p 697.
6. J Louwagie et al., J. Virol. 69, 263 (1995).
7. C. Y. Ou et al., Lancet 341, 1171 (1993)
8. T. A. Peterman, W. Cates Jr., J. N. Wasserheit, in AIDS: Etiology, Diagnosis, Treatment and Prevention, V. T. DeVita Jr et al , Eds (Lippincott, Philadelphia, 1992), pp. 443-451; M. D. C. Guimaraes, A. Munoz, C. Boschi-Pinto, E. A. Castilho, Am. J. Epidemiol. 142, 538 (1995).
9. T. A. Peterman, W. Cates Jr., J. N. Wasserheit, in AIDS: Etiology, Diagnosis, Treatment and Prevention, V. T. DeVita Jr et al , Eds (Lippincott, Philadelphia, 1992), pp. 443-451; M. D. C. Guimaraes, A. Munoz, C. Boschi-Pinto, E. A. Castilho, Am. J. Epidemiol. 142, 538 (1995).
10. C. Kunanusont et al., Lancet 345, 1078 (1995).
11. L R. Braathen, G. Ramirez, R O. F. Kunze, H. Gelderblom, ibid ii, 1904 (1987); M. Landor, Z. Harish, A Rubenstein, Am. J. Med. 87, 489 (1989)
12. L R. Braathen, G. Ramirez, R O. F. Kunze, H. Gelderblom, ibid ii, 1904 (1987); M. Landor, Z. Harish, A Rubenstein, Am. J. Med. 87, 489 (1989)
13. N Dussere et al., J. Invest Dermatol 99, 998 (1992).
14. P. Delorme et al., Res. Virol. 144, 53 (1993).
15. T. Lehner, L. Hussain, J. Wilson, M Chapman, Nature 353, 709 (1991).
16. M. B M Teunissen, J Wormmeester, M L. Kapsenberg, J. D. Bos, J. Invest. Dermatol. 91, 358 (1988).
17. LCs were extracted from normal human skin. Epidermal suspension and enrichment of LCs followed the protocol of Teunissen et al. (13), with some modifications [H.-N. Liu, Y.-T Chang, C -K. Wong, Clin. Exp. Dermatol. 19, 113 (1994)]. Skin tissue was digested overnight at 4°C with 2 mg/ml of dispase in RPMI media with 20% fetal calf serum (FCS) and 1% antibiotics. The epidermis was separated and incubated for 15 min with trypsin (0.005%) and deoxyribonuclease (100 U/ml) in phosphate-buffered saline (PBS). The cell suspension was loaded on a discontinuous Ficoll-Metrizoate gradient LCs were recovered from two interfaces, one between the sample and the gradient and the second between layers with densities of 1 068 and 1 057 g/ml. Purity was estimated with immunofluorescence staining with CD1a [OKT6 (Ortho)], CD3, and CD14. The cells were maintained in RPMI media with 20% FCS and 1% antibiotics. No clumping of LCs with keratinocytes was observed. The viability according to Trypan Blue exclusion was higher than 85% for the period of observation in the assay.
18. The classification system is detailed in Centers for Disease Control (CDC), Morb. Mortal. Wkly. Rep. 35, 334 (1986).
19. W.-K. Wang, M. Essex, T -H. Lee, AIDS Res. Human Retroviruses 11, 185 (1995)
20. PBMCs from HIV-1-seronegative individuals were purified by the Ficoll-Hypaque method, stimulated with 10 μg/ml of phytohemagglutinin A (PHA) (Sigma) for 72 hours, and maintained in RPMI 1640 with 20% fetal bovine serum, 10 U/ml of recombinant human interleukin-2, 100 U/ml of penicillin, and 100 μg/ml of streptomycin.
21. 6 PBMCs per cubic centimeter and RPMI 1640 plus 5% (v/v) human serum and 20% fetal bovine serum. After 5 days, cells were washed twice with PBS and maintained with RPMI 1640 with 20% fetal bovine serum, 100 U/ml of penicillin, and 100 μg/ml of streptomycin.
22. 6 cells/ml in the same media as for MDMs and PMBCs.
23. 6 MT-2 cells were challenged with 1 ng/ml of p24 from each isolate on day 1. All the LC assays were done 24 hours after the extraction and enrichment of the cells Assays with MDMs were started 4 days after the removal of nonadherent cells. Cell cultures were inoculated with each isolate for 18 hours at 37°C, washed with PBS, and resuspended in fresh complete media. Infections with PBMCs, MDMs, and MT-2 cells were done twice, and LC infections were done in duplicate with at least two different LC preparations To determine p24 levels, we obtained culture supematants by removing cells and cell debris after centrifugation at 3500 rpm for 10 min from LCs, PBMCs, and MDMs on days 7, 14, and 21. Standard dilutions were done in each sample, and the procedure was performed according to the manufacturer's protocol (NEN-Dupont Core profile enzymelinked immunosorbent assay).
24. L Soto-Ramirez et al., unpublished results.
25. J. Palacio et al., Res Virol. 145, 155 (1994).
26. X. Tan, R. Pearce-Prat, D. M. Phillips, J. Virol. 67, 6447 (1993).
27. K. Rappersberger et al., Intervirology 29, 185 (1988).
28. A. Gianetti et al., J. Acquired Immune Defic. Syndr. 6, 329 (1993); M. Henry, A. Uthman, C. Ballaun, G. Stingl, E. Tschachler, J. Invest. Dermatol. 103, 593 (1994).
29. A. Gianetti et al., J. Acquired Immune Defic. Syndr. 6, 329 (1993); M. Henry, A. Uthman, C. Ballaun, G. Stingl, E. Tschachler, J. Invest. Dermatol. 103, 593 (1994).
30. C. J. Miller et al., J. Virol. 63, 4277 (1989); C. J. Miller et al , Am. J. Pathol 141, 655 (1992); C. J. Miller et al., Lab Invest. 70, 225 (1994).
31. C. J. Miller et al., J. Virol. 63, 4277 (1989); C. J. Miller et al , Am. J. Pathol 141, 655 (1992); C. J. Miller et al., Lab Invest. 70, 225 (1994).
32. C. J. Miller et al., J. Virol. 63, 4277 (1989); C. J. Miller et al , Am. J. Pathol 141, 655 (1992); C. J. Miller et al., Lab Invest. 70, 225 (1994).
33. G. J. Nuovo, A. Forde, P. MacConnell, R. Fahrenwald, Am. J. Pathol. 143, 40 (1993).
34. F. A. Plummer, J. N. Sirnonsen, D. W. Cameron, J. Infect. Dis. 163, 233 (1991); European Study Group, Br. Med. J 304, 809 (1992); K. A. Hamed et al., J. Infect. Dis. 167, 798 (1993); A. Nicolosi, M. Musicco, A. Saracco, A. Lazzarin, J. Acquired Immune Defic. Syndr. 7, 296 (1994).
35. F. A. Plummer, J. N. Sirnonsen, D. W. Cameron, J. Infect. Dis. 163, 233 (1991); European Study Group, Br. Med. J 304, 809 (1992); K. A. Hamed et al., J. Infect. Dis. 167, 798 (1993); A. Nicolosi, M. Musicco, A. Saracco, A. Lazzarin, J. Acquired Immune Defic. Syndr. 7, 296 (1994).
36. F. A. Plummer, J. N. Sirnonsen, D. W. Cameron, J. Infect. Dis. 163, 233 (1991); European Study Group, Br. Med. J 304, 809 (1992); K. A. Hamed et al., J. Infect. Dis. 167, 798 (1993); A. Nicolosi, M. Musicco, A. Saracco, A. Lazzarin, J. Acquired Immune Defic. Syndr. 7, 296 (1994).
37. F. A. Plummer, J. N. Sirnonsen, D. W. Cameron, J. Infect. Dis. 163, 233 (1991); European Study Group, Br. Med. J 304, 809 (1992); K. A. Hamed et al., J. Infect. Dis. 167, 798 (1993); A. Nicolosi, M. Musicco, A. Saracco, A. Lazzarin, J. Acquired Immune Defic. Syndr. 7, 296 (1994).
38. We acknowledge support of the research staff of the Fenway Community Health Center, especially R. Goldstein. This research was supported in part by grants CA 39805 and HL 33774 from NIH and by a grant from the Massachusetts Department of Public Health L.E S.-R, R S., C.A., and P.A were supported by training grant 5 D43 TW0004 from the Fogarty International Center, NIH. The authors thank K. MacArthur for editorial assistance.